InflaRx Announces Closing of $75 Million Public Offering of Common Shares and One-Year Warrants
March 01 2021 - 4:01PM
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical
company developing anti-inflammatory therapeutics by targeting the
complement system, announced today that it has completed its
underwritten public offering of 15,000,000 common shares at a price
of $5.00 per share. For each common share purchased, an investor
received a warrant to purchase a common share at an exercise price
of $5.80. The gross proceeds to InflaRx from the offering were
approximately $75 million, before deducting the underwriting
discount and other offering expenses and excluding the exercise of
any warrants. The Company intends to use the net proceeds from the
offering primarily to fund research and development expenses for
its clinical and preclinical research and development activities
and for working capital and general corporate purposes.
Guggenheim Securities, LLC and Raymond James
& Associates, Inc. served as joint book-running managers for
the offering.
A shelf registration statement relating to the
securities being sold in this offering was filed with the U.S.
Securities and Exchange Commission (the “SEC”) and was declared
effective by the SEC on July 17, 2020. The offering was made only
by means of a prospectus and a prospectus supplement. A prospectus
supplement and accompanying prospectus related to the offering have
been filed with the SEC and are available at the SEC’s website
located at www.sec.gov. Copies of the prospectus supplement and
accompanying prospectus related to the offering may be obtained by
contacting Guggenheim Securities, LLC, Attention: Equity Syndicate
Department, 330 Madison, 8th Floor, New York, NY 10017, or by
telephone at (212) 518-9544, or by email to
GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities, nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About InflaRx N.V.:
InflaRx (Nasdaq: IFRX) is a clinical-stage
biopharmaceutical company focused on applying its proprietary
anti-C5a technology to discover and develop first-in-class, potent
and specific inhibitors of C5a. Complement C5a is a powerful
inflammatory mediator involved in the progression of a wide variety
of autoimmune and other inflammatory diseases. InflaRx was founded
in 2007, and the group has offices and subsidiaries in Jena and
Munich, Germany, as well as Ann Arbor, MI, USA.
Contacts:
InflaRx N.V.
Jordan Zwick – Chief Strategy OfficerEmail:
IR@inflarx.deTel: +1 917-338-6523
MC Services AG
Katja Arnold, Laurie Doyle, Andreas
JungferEmail: inflarx@mc-services.euEurope: +49 89-210 2280U.S.:
+1-339-832-0752
FORWARD-LOOKING STATEMENTSThis press release
contains forward-looking statements. All statements other than
statements of historical fact are forward-looking statements, which
are often indicated by terms such as “may,” “will,” “should,”
“expect,” “plan,” “anticipate,” “could,” “intend,” “target,”
“project,” “believe,” “estimate,” “predict,” “potential” or
“continue” and similar expressions. Forward-looking statements
appear in a number of places throughout this release and may
include statements regarding our intentions, beliefs, projections,
outlook, analyses and current expectations concerning, among other
things, our ongoing and planned preclinical development and
clinical trials; the impact of the COVID-19 pandemic on the
Company; the timing and our ability to commence and conduct
clinical trials; potential results from current or potential future
collaborations; our ability to make regulatory filings, obtain
positive guidance from regulators, and obtain and maintain
regulatory approvals for our product candidates; our intellectual
property position; our ability to develop commercial functions;
expectations regarding clinical trial data; our results of
operations, cash needs, financial condition, liquidity, prospects,
future transactions, growth and strategies; the industry in which
we operate; the trends that may affect the industry or us and the
risks uncertainties and other factors described under the heading
“Risk Factors” in InflaRx’s periodic filings with the Securities
and Exchange Commission. These statements speak only as of the date
of this press release and involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. Given these risks,
uncertainties and other factors, you should not place undue
reliance on these forward-looking statements, and we assume no
obligation to update these forward-looking statements, even if new
information becomes available in the future, except as required by
law.
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Sep 2023 to Sep 2024